Overview

Mechanistic Evaluation of Response in TRD (MERIT)

Status:
Completed
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in delaying relapse of depressive symptoms in patients with TRD who are in stable remission after treatment with AXS-05.
Phase:
Phase 2
Details
Lead Sponsor:
Axsome Therapeutics, Inc.